Jefferies Financial Group assumed coverage on shares of Oruka Therapeutics (NASDAQ:ORKA – Free Report) in a research report sent to investors on Friday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $40.00 price objective on the stock.
Separately, Wedbush initiated coverage on shares of Oruka Therapeutics in a research note on Wednesday, September 4th. They set an outperform rating and a $40.00 target price on the stock.
View Our Latest Report on Oruka Therapeutics
Oruka Therapeutics Trading Up 4.1 %
Oruka Therapeutics Company Profile
ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.
Featured Stories
- Five stocks we like better than Oruka Therapeutics
- What Are Growth Stocks and Investing in Them
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- What is a support level?
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- The Most Important Warren Buffett Stock for Investors: His Own
- 5 Oversold Stocks to Buy Right Now
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
